Skip to main
BCPC

Balchem (BCPC) Stock Forecast & Price Target

Balchem (BCPC) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Balchem is poised for continued growth, as the company's reported financial results for the fourth quarter of 2025 showed record sales of $263.6 million, a 9.8% increase from the previous year. With a focus on human nutrition and health, the company's Strong HNH segment has been the driving force behind this growth, with projected revenue of $693 million in 2026 and $713 million in 2027. Additionally, Balchem's effective tax rate is expected to rise only modestly and the absence of tariffs on its nutraceutical products provides further competitive advantage in the market.

Bears say

Balchem is expected to continue facing challenges in its Animal Nutrition and Health segment, which has been negatively impacted by increased input costs. Despite a positive outlook for its Human Nutrition and Health segment, its overall valuation metrics have not improved, and the company is likely to be affected by continued market risks and uncertainties such as inflationary pressures and potential disruption to its European business. Our valuation approach yields a 12-month price objective of $190 per share, but significant risks remain, including slower growth in core businesses and potential hurdles in launching new products.

Balchem (BCPC) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Balchem (BCPC) Forecast

Analysts have given Balchem (BCPC) a Buy based on their latest research and market trends.

According to 2 analysts, Balchem (BCPC) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $188.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $188.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Balchem (BCPC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.